Your browser doesn't support javascript.
Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region.
Del Prete, Eleonora; Francesconi, Alessio; Palermo, Giovanni; Mazzucchi, Sonia; Frosini, Daniela; Morganti, Riccardo; Coleschi, Piero; Raglione, Laura Maria; Vanni, Paola; Ramat, Silvia; Novelli, Alessio; Napolitano, Alessandro; Battisti, Carla; Giuntini, Martina; Rossi, Carlo; Menichetti, Chiara; Ulivelli, Monica; De Franco, Valentino; Rossi, Simone; Bonuccelli, Ubaldo; Ceravolo, Roberto.
  • Del Prete E; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy.
  • Francesconi A; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy.
  • Palermo G; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy.
  • Mazzucchi S; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy.
  • Frosini D; Department of Medical Specialties, Neurology Unit, AOUP, Pisa, Italy.
  • Morganti R; Section of Statistics, University Hospital of Pisa, Pisa, Italy.
  • Coleschi P; Unit of Neurology, Ospedale San Donato Arezzo, Arezzo, Italy.
  • Raglione LM; Unit of Neurology of Florence, Central Tuscany Local Health Authority, San Giovanni Di Dio Hospital, Firenze, Italy.
  • Vanni P; Ospedale S. Maria Annunziata, ASL Centro, Firenze, Italy.
  • Ramat S; Parkinson Unit, Department of NeuroMuscular- Skeletal and Sensorial Organs, AO Careggi-Firenze, Firenze, Italy.
  • Novelli A; Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Firenze, Italy.
  • Napolitano A; Unit of Neurology, Hospital of Lucca, Azienda USL Toscana Nordovest, Pisa, Italy.
  • Battisti C; Department of Medical-Surgical Science and Neuroscience, University of Siena, Siena, Italy.
  • Giuntini M; Unit of Neurology, S. Stefano Prato Hospital, Azienda Toscana Centro, Pisa, Italy.
  • Rossi C; Unit of Neurology, Pontedera Hospital, Azienda Toscana nord-ovest, Pisa, Italy.
  • Menichetti C; S.O.C. Neurology, Pistoia, Italy.
  • Ulivelli M; Department of Medicine, Surgery and Neuroscience, Unit of Neurology and Clinical Neurophysiology, University of Siena, Siena, Italy.
  • De Franco V; Department of Medicine, Surgery and Neuroscience, Unit of Neurology and Clinical Neurophysiology, University of Siena, Siena, Italy.
  • Rossi S; Department of Medicine, Surgery and Neuroscience, Unit of Neurology and Clinical Neurophysiology, University of Siena, Siena, Italy.
  • Bonuccelli U; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy.
  • Ceravolo R; Clinical and Experimental Medicine Department, Neurology Unit, University of Pisa, Via Roma 67, Pisa, Italy. roberto.ceravolo@unipi.it.
J Neurol ; 268(4): 1179-1187, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-743721
ABSTRACT

BACKGROUND:

If Parkinson's Disease (PD) may represent a risk factor for Coronavirus disease 2019 (COVID-19) is debated and there are few data on the direct and indirect effects of this pandemic in PD patients.

OBJECTIVE:

In the current study we evaluated the prevalence, mortality and case-fatality of COVID-19 in a PD cohort, also exploring possible risk factors. We also aimed to investigate the effect of lockdown on motor/non-motor symptoms in PD patients as well as their acceptability/accessibility to telemedicine.

METHOD:

A case-controlled survey about COVID-19 and other clinical features in PD patients living in Tuscany was conducted. In non-COVID-19 PD patients motor/non-motor symptoms subjective worsening during the lockdown as well as feasibility of telemedicine were explored.

RESULTS:

Out of 740 PD patients interviewed, 7 (0.9%) were affected by COVID-19, with 0.13% mortality and 14% case-fatality. COVID-19 PD patients presented a higher presence of hypertension (p < 0.001) and diabetes (p = 0.049) compared to non-COVID-19. In non-COVID-19 PD population (n = 733) about 70% did not experience a subjective worsening of motor symptoms or mood, anxiety or insomnia. In our population 75.2% of patients was favorable to use technology to perform scheduled visits, however facilities for telemedicine were available only for 51.2% of cases.

CONCLUSION:

A higher prevalence of COVID-19 respect to prevalence in Tuscany and Italy was found in the PD population. Hypertension and diabetes, as for general population, were identified as risk factors for COVID-19 in PD. PD patients did not experience a subjective worsening of symptoms during lockdown period and they were also favorable to telemedicine, albeit we reported a reduced availability to perform it.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-020-10002-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-020-10002-6